Piper Sandler on BridgeBio Pharma (BBIO): 'Attruby Launch In Early Innings Looks Strong'
Tweet Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $46.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
